UBS Group
AUPH icon

UBS Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

UBS Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Sell
191,600
-194,256
-50% -$3.1M ﹤0.01% 4613
2026
Q1 		$5.72M Buy
385,856
+131,184
+52% +$1.92M ﹤0.01% 3932
2025
Q4 		$4.06M Buy
254,672
+55,924
+28% +$793K ﹤0.01% 4238
2025
Q3 		$2.2M Sell
198,748
-126,881
-39% -$1.39M ﹤0.01% 4853
2025
Q2 		$2.76M Buy
325,629
+68,490
+27% +$549K ﹤0.01% 4480
2025
Q1 		$2.07M Buy
257,139
+43,866
+21% +$355K ﹤0.01% 4675
2024
Q4 		$1.92M Buy
213,273
+62,574
+42% +$511K ﹤0.01% 4760
2024
Q3 		$1.1M Buy
150,699
+13,525
+10% +$83.9K ﹤0.01% 4569
2024
Q2 		$783K Sell
137,174
-63,608
-32% -$335K ﹤0.01% 4644
2024
Q1 		$1.01M Sell
200,782
-52,706
-21% -$358K ﹤0.01% 4597
2023
Q4 		$2.28M Buy
253,488
+61,306
+32% +$505K ﹤0.01% 3668
2023
Q3 		$1.49M Sell
192,182
-50,188
-21% -$491K ﹤0.01% 3736
2023
Q2 		$2.35M Buy
242,370
+110,901
+84% +$1.15M ﹤0.01% 3374
2023
Q1 		$1.44M Buy
131,469
+84,912
+182% +$748K ﹤0.01% 3762
2022
Q4 		$201K Buy
46,557
+9,832
+27% +$57K ﹤0.01% 5445
2022
Q3 		$276K Sell
36,725
-113,293
-76% -$981K ﹤0.01% 4833
2022
Q2 		$1.51M Sell
150,018
-25,549
-15% -$286K ﹤0.01% 3370
2022
Q1 		$2.17M Buy
175,567
+61,781
+54% +$955K ﹤0.01% 3353
2021
Q4 		$2.6M Sell
113,786
-123,943
-52% -$2.94M ﹤0.01% 3500
2021
Q3 		$5.26M Sell
237,729
-22,476
-9% -$357K ﹤0.01% 2621
2021
Q2 		$3.37M Buy
260,205
+5,373
+2% +$68.4K ﹤0.01% 3069
2021
Q1 		$3.31M Buy
254,832
+38,749
+18% +$562K ﹤0.01% 3024
2020
Q4 		$2.99M Buy
216,083
+46,767
+28% +$681K ﹤0.01% 2987
2020
Q3 		$2.49M Buy
169,316
+67,534
+66% +$978K ﹤0.01% 2851
2020
Q2 		$1.65M Sell
101,782
-20,620
-17% -$330K ﹤0.01% 3055
2020
Q1 		$1.78M Buy
122,402
+39,442
+48% +$696K ﹤0.01% 2863
2019
Q4 		$1.68M Buy
82,960
+75,906
+1,076% +$699K ﹤0.01% 3724
2019
Q3 		$38K Buy
7,054
+611
+9% +$3.7K ﹤0.01% 6342
2019
Q2 		$42K Sell
6,443
-581
-8% -$3.7K ﹤0.01% 6063
2019
Q1 		$46K Sell
7,024
-1,158
-14% -$7.68K ﹤0.01% 5606
2018
Q4 		$55K Sell
8,182
-120,788
-94% -$697K ﹤0.01% 5999
2018
Q3 		$857K Buy
128,970
+8,535
+7% +$47.9K ﹤0.01% 3985
2018
Q2 		$678K Buy
120,435
+5,000
+4% +$27.9K ﹤0.01% 4088
2018
Q1 		$599K Sell
115,435
-3,400
-3% -$18.2K ﹤0.01% 4088
2017
Q4 		$538K Buy
118,835
+26,000
+28% +$144K ﹤0.01% 4241
2017
Q3 		$582K Sell
92,835
-5,705
-6% -$36K ﹤0.01% 4102
2017
Q2 		$604K Sell
98,540
-13,774
-12% -$92.8K ﹤0.01% 3984
2017
Q1 		$824K Buy
112,314
+13,405
+14% +$61.9K ﹤0.01% 3689
2016
Q4 		$208K Buy
98,909
+29,549
+43% +$95.1K ﹤0.01% 4762
2016
Q3 		$209K Buy
+69,360
New +$187K ﹤0.01% 4520
2016
Q2 		– Sell
-2,019
Closed -$6K – 7709
2016
Q1 		$6K Sell
2,019
-14,891
-88% -$36K ﹤0.01% 6908
2015
Q4 		$42K Buy
+16,910
New +$45.9K ﹤0.01% 5966

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's AUPH Position: Q2 2026 in Review

UBS Group reduced its Aurinia Pharmaceuticals (AUPH) stake by 50% in Q2 2026, selling an estimated $3.1M and leaving 191,600 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #4613.

UBS Group first reported a position in AUPH in Q4 2015 and has held it in 42 quarters since. The position peaked at $5.72M in Q1 2026. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • UBS Group held 191,600 shares of Aurinia Pharmaceuticals worth $3.25M as of Q2 2026.
  • UBS Group sold 194,256 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $3.1M.
  • Aurinia Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4613 holding.
  • UBS Group first reported a position in Aurinia Pharmaceuticals in Q4 2015 and has held it in 42 quarters since.
  • UBS Group's Aurinia Pharmaceuticals position peaked at $5.72M in Q1 2026.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.